Author

Janki Patel

Dana-Farber/Boston Children's Cancer and Blood Disorders CenterPrimary ORCID profile (0000-0002-8140-9347 · 3 papers)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Janki PateliD3 papers · Salk Institute for Biological Studies

Biology Disciplines

Click to filter author papers

Neuroscience· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 1 Organism:mouse· 1

Frequent Co-Authors

Alessandra BiffiiD· 1 shared Ana Zguro· 1 shared Eleonora CavalcaiD· 1 shared Marco PevianiiD· 1 shared Odella C. Jno-Charles· 1 shared Paolo Cabras· 1 shared Rajesh KumariD· 1 shared Rita MilazzoiD· 1 shared

Activity by Year

2023-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperNeuroscience

Alessandra BiffiORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

An innovative hematopoietic stem cell gene therapy approach benefits CLN1 disease in the mouse model

Marco Peviani, Sabyasachi Das, Janki Patel, Odella C. Jno-Charles, Rajesh Kumar, Ana Zguro, Tyler D. Mathews, Paolo Cabras, Rita Milazzo, Eleonora Cavalca, Valentina Poletti, Alessandra Biffi

This study demonstrates that gene therapy using hematopoietic stem cells can mitigate CLN1 disease symptoms in mice, with enhanced benefits from hPPT1 overexpression and combined transplantation approaches.

EMBO Molecular Medicine · Mar 6, 2023Peer-reviewedNeuroscience